The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo.

Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, MA 02129, USA.
Journal of Clinical Investigation (Impact Factor: 13.77). 08/2007; 117(7):1961-7. DOI: 10.1172/JCI29877
Source: PubMed

ABSTRACT NO plays critical roles in vascular function. We show that modulation of the eNOS serine 1179 (S1179) phosphorylation site affects vascular reactivity and determines stroke size in vivo. Transgenic mice expressing only a phosphomimetic (S1179D) form of eNOS show greater vascular reactivity, develop less severe strokes, and have improved cerebral blood flow in a middle cerebral artery occlusion model than mice expressing an unphosphorylatable (S1179A) form. These results provide a molecular mechanism by which multiple diverse cardiovascular risks, such as diabetes and obesity, may be centrally integrated by eNOS phosphorylation in vivo to influence blood flow and cardiovascular disease. They also demonstrate the in vivo relevance of posttranslational modification of eNOS in vascular function.

  • Source
    Stroke 04/2009; 40(5):e407-e407. DOI:10.1161/STROKEAHA.109.549485 · 6.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Receptor for Advanced Glycation End products (RAGE) is one of the most important factors implicated in diabetes, cardiovascular diseases, neurodegenerative diseases, and cancer. It is a pattern recognition receptor, by virtue of its ability to interact with multiple ligands; RAGE activates several signal transduction pathways through involvement of various kinases, which phosphorylate their respective substrates. Only few substrates have been known to be phosphorylated in response to activation by RAGE (e.g.NF-кB), however it is possible that these kinases can phosphorylate multiple substrates depending upon their expression and localization, leading to altered cellular responses in different cell types and conditions. One such example, Glycogen synthase kinase 3 beta (GSK3β) which is known to phosphorylate glycogen synthase, acts downstream to RAGE and hyperphosphorylates Microtubule Associated Protein Tau (MAPT) causing neuronal damage. Thus, it is important to understand the role of various RAGE activated kinases and their substrates. Therefore, we have reviewed here the details of RAGE activated kinases in response to different ligands and their respective phosphoproteome. Further, we discuss the analysis of the data mined for known substrates of these kinases from PhosphoSitePlus ( database, and the role of some of the important substrates involved in cancer, diabetes, cardiovascular diseases and neurodegenerative diseases. In summary, this review provides information on RAGE activated kinases and their phosphoproteome, which will be helpful in understanding the possible role of RAGE and its ligands in progression of diseases.This article is protected by copyright. All rights reserved
    Proteomics 01/2015; 15(2-3). DOI:10.1002/pmic.201400169 · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel tetramethylpyrazine derivative, CXC195, has been recently shown to protect against cerebral ischemia-reperfusion (I/R) injury. However, the detailed mechanisms underlying the neuroprotection of CXC195 are still unclear. The aim of the present study was to investigate the effects of CXC195 on the phosphorylation of endothelial nitric oxide synthase (eNOS) in response to cerebral I/R and to determine whether phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway might be involved. An in vitro model of oxygen glucose deprivation (OGD) which was performed on primary cultured human aortic endothelial cells (HAECs) and an in vivo middle cerebral artery occlusion (MCAO) model that was performed on Wistar rats were used in this study. CXC195 increased nitric oxide (NO) production and the phosphorylation but not the protein level of eNOS in HAECs subjected to 1 h OGD followed by reperfusion. In addition, CXC195 increased the phosphorylation of Akt; inhibition of PI3K/Akt pathway by a specific inhibitor, wortmannin, suppressed CXC195-induced NO release in HAECs. Consistently, CXC195 treatment significantly restored the phosphorylations of eNOS and Akt in the cortical penumbra of rats subjected to 2 h MCAO followed by reperfusion. Moreover, wortmannin abolished CXC195-induced eNOS phosphorylation and neuroprotection as evidenced by a reversal of the reduction in infarct volume and neurobehavioral outcomes. In conclusion, CXC195 induced phosphorylation of eNOS by activation of PI3K/Akt signaling under pathological cerebral I/R conditions, which provided a novel explanation for the neuroprotective effect of CXC195.
    Neurochemical Research 11/2014; DOI:10.1007/s11064-014-1485-x · 2.55 Impact Factor


Available from
Jun 5, 2014